Key result
Mitral valve repair in patients with infective endocarditis resulted in a 3-year mortality rate of 26% compared to 36% for valve replacement, though the difference was not significant.
Why the study?
Valve repair is standard for native mitral regurgitation, but its feasibility when caused by acute infective endocarditis is debated.
Does mitral valve repair improve mortality and freedom from recurrent endocarditis compared to mitral valve replacement in patients with native mitral valve infective endocarditis?
Cohort (n=90)
No
Does mitral valve repair improve mortality and freedom from recurrent endocarditis compared to mitral valve replacement in patients with native mitral valve infective endocarditis?
Mitral valve repair for infective endocarditis is feasible and yields comparable mid-term mortality and relapse rates to valve replacement, supporting its use when anatomically possible.
Answers are grounded in this paper and cite their sources.
Repair yields comparable mid-term outcomes to replacement in this cohort; leaves open randomized confirmation of benefit in native mitral endocarditis.
Background Valve repair is the treatment of choice for native mitral valve regurgitation. The feasibility of repair when the defect is caused by acute infective endocarditis (IE) is debated. This study aims to compare the outcome of repair and replacement procedures, to report the rate of repair in a single surgical center, and to review the literature on this topic. Results We retrospectively analyzed 108 patients with native mitral IE, potentially eligible for surgical repair. Of these 108, 90 (83%) underwent surgery, and 18 were treated conservatively. Among the 90 surgical patients, 57 (63%) underwent valve replacement and 33 valve repair (37%). The mean follow-up duration was 3 years. The two primary endpoints were mortality and freedom from recurrent endocarditis. Secondary endpoints were the post-operative incidence of major adverse events (hospitalization for any cause, pacemaker implantation, new onset of atrial fibrillation, sternal dehiscence), left ventricular systolic function (LVSF), and valvular function at 1-year echocardiographic follow-up. All-cause mortality was lower for valve repair, although not significantly (p = 0.86), as well as nonfatal adverse events (p = 0.92) and relapse rate (p = 0.20) at 3 years. We did not find differences between the two groups at echocardiographic follow-up, neither for left ventricular systolic function (p = 0.22), nor for valvular continence (p = 0.28). Conclusions In our experience, the mid-term outcome of repair in IE is comparable to valve replacement and should be considered whenever possible, as in degenerative valve disease. The review of the literature supports this strategy.
No takes yet. Share an insight, caveat, or question.
Scheggi et al. (2020) conducted a cohort in Native mitral valve infective endocarditis (n=90). Mitral valve repair vs. Mitral valve replacement was evaluated on All-cause long-term (3 years) mortality (p=0.86). Mitral valve repair in patients with infective endocarditis resulted in a 3-year mortality rate of 26% compared to 36% for valve replacement, though the difference was not significant.
Synapse has enriched 10 related papers. Consider them for comparative context: